Bicycle Therapeutics of the UK has raised £20m in a series A financing round for the clinical development of its therapeutic bicycle drug candidates in oncology.
The existing investor syndicate comprising Atlas Venture, Novartis Venture Fund, SR One, SV Life Sciences and Astellas Venture Management participated...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
